Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5165)
All Articles published online
|
Publishing Process of This Article
|
Aug 10, 2014 (publication date) through Jun 12, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Markopoulos C, Kykalos S, Mantas D. Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World J Clin Oncol 2014; 5(3): 374-381 [PMID: 25114852 DOI: 10.5306/wjco.v5.i3.374] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v5/i3/374.htm |
| Number | Citing Articles |
| 1 |
Razan Eskandrani, Lamees S. Al-Rasheed, Siddique Akber Ansari, Ahmed H. Bakheit, Abdulrahman A. Almehizia, Maha Almutairi, Hamad M. Alkahtani. Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies. Molecules 2023; 28(11): 4271 doi: 10.3390/molecules28114271
|
| 2 |
T. J. Thomas, Thresia Thomas, Shali John, Hui-Chen Hsu, PingAr Yang, Tuomo A. Keinänen, Mervi T. Hyvönen. Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer. Amino Acids 2016; 48(10): 2293 doi: 10.1007/s00726-016-2300-6
|
| 3 |
G S Hwang, R Bhat, R D Crutchley, M V Trivedi. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. The Pharmacogenomics Journal 2018; 18(2): 201 doi: 10.1038/tpj.2017.36
|
| 4 |
Qiu Zhong, Changde Zhang, Qiang Zhang, Lucio Miele, Shilong Zheng, Guangdi Wang. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1621-2
|